The sensitivity, specificity, likelihood ratio, and area under the receiver operating characteristic (ROC) curve were estimated.
Cauda Equina Syndrome
Symptoms may include lower back pain, numbness, weakness, or incontinence.
Early diagnosis and treatment are crucial to prevent permanent neurological damage.
Explore the latest research on effective management strategies using PubCompare.ai's AI-powered platform, which can help you locate and compare relevant protocols from literature, preprints, and patents.
Streamline your cauda equina syndrome research and find the best approaches for your needs.
Most cited protocols related to «Cauda Equina Syndrome»
The sensitivity, specificity, likelihood ratio, and area under the receiver operating characteristic (ROC) curve were estimated.
Study eligibility criteria
Published studies were included if they fulfilled any of the following criteria: |
• Developed and described an original classification system for back pain that included adult patients with low back related leg pain (LBLP). Leg pain was defined as pain below the gluteal fold. |
Exclusion criteria: |
• Studies looking at specific spinal “red flag” conditions such as cauda equina syndrome, tumours or spinal fractures or a specific disease cohort such as diabetes. |
±12.50 cm, weight = 61.17 ±9.60 kg, duration = 13.65 ±10.24 months) volunteered for this
study at a local orthopedic clinic. Subjects had pain scores ranging from 5 –7 on a visual
analogue scale, and scores of 40–60% on the Korean version of the Oswestry disability index.
LBP was defined as current symptoms of pain and/or numbness between the twelfth rib and
buttocks with or without symptoms in one or both legs that limited function9 (link)). Participants were excluded if they had
received lumbar surgery were unable to lie prone or supine for a minimum of 20 minutes or
presented with potentially serious conditions such as cauda equina syndrome, major or
rapidly progressing neurologic deficit, fracture, cancer, infection, or systemic
diseases.
This study used ADIM to draw in and hold the lower abdomen at maximum expiration in a
supine position. Verbal instructions for the ADIM were “Draw your belly inward and upward
while breathing normally, then hold the contraction for 10 seconds.” ADIM was performed 3
times, with 10 second rest periods10 ).
Before progressing to the main experiment, the subjects were educated in the method of ADIM
and practiced 3 sets to decrease errors arising from incorrect performance.
Rest and ADIM thicknesses of the TrA, IO and EO were obtained using a LOGIQ P5(GE
Healthcare, USA) with a 7.5-MHz linear probe. Conductive gel was placed between the
transducer and subjects skin. The measurements were taken as described by Richardson et al.
with the subjects in the supine hook lying position with the transducer placed just superior
to the iliac crest along the axillary line11 ). The transducer head location was marked on the right-hand side of
each subject midway between the lowest rib and the apex of the ilium. This has been shown to
be the thickest point of the Tra, and demonstrates the clearest simultaneous images of Tra,
IO and EO12 ). The thickness of each of the
3 muscles (TrA, IO, and EO muscles) was measured at the center line of the image.
The average of the 3 trials was used in the analysis. In processing data, the version 12.0
program was used. In order to assess the intra-examiner and inter-examiner of the ultrasound
imaging intra class coefficients (ICC) were computed.
Exclusion criteria have been developed to screen out patients with: safety concerns for either SM or the sensorimotor testing (e.g. bleeding disorders, sensitivity to tape, contra-indication to SM, pregnancy); unconfirmed safety (e.g. joint replacement, pacemaker); safety concern related to equipment weight capacity (e.g. extreme obesity with weight greater than or equal to 307 pounds); conditions that may result in intolerance to biomechanical testing or treatment protocols (e.g. vascular claudication, bone and joint abnormality, inflammatory or destructive tissue changes to the spine, osteoporosis, Quebec Task Force classification 4, 5, 6, 8, 9, 10, 11 [73 (link)]); overall condition too poor to tolerate treatment and biomechanical testing procedures; conditions that may interfere with data collection (e.g. neuromuscular diseases, peripheral neuropathies, prior spinal surgery); conditions that might interfere with data collection and ability to comply with study protocol (e.g. suspicion of drug or alcohol abuse, uncontrolled hypertension, depression according to the Beck Depression Inventory-II©); condition which requires surgical evaluation (e.g. cauda equina syndrome); and other concerns which may make it difficult to fully consent, interfere with study compliance, or constitute a possible data confounder (e.g. inability to read or verbally comprehend English), indicators for diagnostic procedures beyond dipstick urinalysis or x-rays, retention of legal advice for an open or pending case related to LBP and ongoing treatment for LBP by other health care providers.
Upon completion of standard discectomy, the treating surgeon will assess the feasibility of AF re-approximation and make the final decision whether the patient will receive UPAL gel implantation and be officially enrolled in the study [1 (link)]. The complete inclusion/exclusion criteria are as follows [1 (link)].
Inclusion criteria.
Candidate for lumbar discectomy.
Radiographic findings corroborating symptoms of IVD herniation.
Condition unresponsive to 6 consecutive weeks of therapy or experiencing acute/uncontrolled leg pain, defined as a score >80 on the 100-mm visual analog scale (VAS), in which higher scores representing worse pain correspond to worse pain.
Single-level lumbar IVD herniation.
Persistent and predominant leg pain (score >40 on the 100-mm VAS)
Age between 20 and 49 years (inclusively).
Willingness to provide written informed consent, fill in all necessary questionnaires, and return for follow-up.
Previous surgery involving a lumbar level.
Prior or planned spinal fusion involving a lumbar level.
Local kyphosis involving the affected disc level, evident on plain radiography of the lumbar spine in the flexion, neutral or extension position.
Spondylolisthesis or retrolisthesis above grade 1 at the affected level.
Cauda equina syndrome.
Acute local or systemic infection.
Active malignancy or other similar comorbidities.
Current drug or alcohol dependency.
Current significant emotional disturbance.
Current fracture, tumour, and/or deformity of the lumbar spine.
Current or planned pregnancy.
Currently enrolled in other research that could confound the results of the present trial.
Presence of a metal implant or any other contraindication to MRI.
Allergy to sodium alginate revealed upon skin prick testing.
Any other reason judged by an investigator or clinical trial doctor to render the candidate unsuitable for this clinical trial.
Most recents protocols related to «Cauda Equina Syndrome»
The inclusion requirements included: (1) L4 DLS; (2) Meyerding grade I or II; and (3) complete radiographic data, including whole-spine anteroposterior and lateral radiographs and lateral flexion and extension X-ray of the lumbar spine.
The exclusion criteria were as follows: (1) multilevel DLS; (2) isthmic spondylolisthesis; (3) history of prior lumbar trauma, tumor, infection, cauda equina syndrome, or revision surgery; and (4) surgery requiring more than two-level instrumentation and fusion.
Demographic data were collected using electronic medical record reviews, including age, gender, height, weight, and body mass index. Overall, 101 patients were ultimately enrolled in the present study.
Demographic data, such as age, sex, height, weight, and body mass index (BMI), were collected via electronic medical record reviews. The bone mineral density (BMD) at the lumbar spine was assessed via dual-energy X-ray absorptiometry.
The patients were classified into three groups based on the fusion levels. Patients with L5-S1 TLIF and ICS at L4-L5 were assigned to Group A, patients with L4-S1 TLIF and ICS at L3-L4 were assigned to Group B, and those with L3-S1 TLIF and ICS at L2-L3 were assigned to Group C.
Top products related to «Cauda Equina Syndrome»
More about "Cauda Equina Syndrome"
This condition can lead to a range of debilitating symptoms, including lower back pain, numbness, weakness, and incontinence.
Early diagnosis and prompt treatment are crucial to prevent permanent neurological damage and long-term complications.
CES is considered a medical emergency, as the compressed or injured nerves can quickly lead to irreversible nerve damage if left untreated.
The condition may be caused by a variety of factors, such as spinal disc herniation, spinal stenosis, tumors, or traumatic injury to the spine.
Symptoms of CES can vary depending on the severity and location of the nerve compression.
Common signs include lower back pain, bilateral leg pain or weakness, numbness or tingling in the groin, buttocks, or legs, and bladder or bowel dysfunction.
In severe cases, patients may experience complete paralysis of the lower extremities and loss of bowel and bladder control.
Effective management of CES requires a multidisciplinary approach, involving early surgical decompression to relieve the nerve pressure, as well as rehabilitation and supportive care.
Researchers are continuously exploring new treatment strategies, including the use of pharmacological interventions, regenerative therapies, and advanced imaging techniques to improve patient outcomes.
PubCompare.ai's AI-powered platform can be a valuable tool for researchers and clinicians working in the field of CES.
The platform allows users to locate and compare relevant protocols from the literature, preprints, and patents, streamlining the research process and helping to identify the most effective management approaches for their specific needs.
By leveraging the latest advancements in artificial intelligence, PubCompare.ai can help accelerate the development of better treatments and improve the care of patients with this devastating condition.